Top

Published in:

01-06-2015 | Research Article

Decreased expression of microRNA-107 predicts poorer prognosis in glioma

Authors: Yuchen Ji, Yujun Wei, Jianyong Wang, Qiang Ao, Kai Gong, Huancong Zuo

Published in: Tumor Biology | Issue 6/2015

Abstract

The expression level of microRNA-107 (miR-107) has been proved to be decreased in many human malignant cancers. Especially in glioma, accumulating evidence indicates that miR-107 may play important parts in cell proliferation, apoptosis, and invasion in glioma. However, its clinical significance in glioma has not been investigated. This study aims at investigating the relationship between miR-107 expression level and clinical significance and analyzing its value of miR-107 in valuing the prognosis of glioma patients. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of miR-107 in 80 glioma and 17 normal brain tissues. The results showed the miR-107 expression level in glioma tissues was significantly lower than those in normal brain tissues (p < 0.001). The decreased expression of miR-107 in glioma was positively associated with high WHO grade (p < 0.001), low Karnofsky performance score (KPS) (p < 0.001), and large tumor size (p < 0.001) and had a significant impact on overall survival (OS) (p < 0.001) and progression-free survival (PFS) (p < 0.001) according to Kaplan–Meier survival with log-rank test. Finally, Cox regression analyses showed that low miR-107 expression (p < 0.001) might be an independent prognostic parameter to predict poor prognosis. In conclusion, it is the first data to prove that expression level of miR-107 may be a novel and valuable prognostic factor in glioma.

Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.CrossRefPubMed

Zhao W, Wang C, Wang J, Ge A, Li Y, Li W, et al. Relationship between cacyBP/SIP expression and prognosis in astrocytoma. J Clin Neurosci. 2011;18:1240–4.CrossRefPubMed

Zhang X, Yang H, Gong B, Jiang C, Yang L. Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. J Neurooncol. 2012;107:281–8.CrossRefPubMed

Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMed

Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer. 2011;30:739–48.CrossRefPubMedPubMedCentral

Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol. 2013;113:221–8.CrossRefPubMed

Men D, Liang Y, Chen L. Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol. 2014;38:152–6.CrossRefPubMed

Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B. Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas. Pathol Oncol Res 2014.

He J, Deng Y, Yang G, Xie W. MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol. 2013;108:121–5.CrossRefPubMed

10.

Lai NS, Dong QS, Ding H, Miao ZL, Lin YC. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 2014;21:755–60.CrossRefPubMed

11.

Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X. Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol. 2014;31:911.CrossRefPubMed

12.

Wu Z, Wang L, Li G, Liu H, Fan F, Li Z, et al. Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. Mol Cell Biochem. 2013;384:263–8.CrossRefPubMed

13.

Sun B, Pu B, Chu D, Chu X, Li W, Wei D. MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neuro-Oncol. 2013;115:375–80.CrossRef

14.

Chen L, Chen X, Zhang R, Li P, Liu Y, Yan K, et al. MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neuro-Oncol. 2013;112:59–66.CrossRef

15.

He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol. 2013;45:1962–73.CrossRefPubMed

16.

Nakazato Y. The 4th edition of WHO classification of tumours of the central nervous system published in 2007. No Shinkei Geka. 2008;36:473–91.PubMed

17.

Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed). 2012;17:700–12.CrossRef

18.

Zhong KZ, Chen WW, Hu XY, Jiang AL, Zhao J. Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer. Int J Clin Exp Pathol. 2014;7:4545–51.PubMedPubMedCentral

19.

Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, et al. Mir-107 and mir-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014;14:656.CrossRefPubMedPubMedCentral

20.

Feng L, Xie Y, Zhang H, Wu Y. Mir-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29:856–63.CrossRefPubMed

21.

Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, et al. Microrna-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene. 2012;31:4045–53.CrossRefPubMed

22.

Ayala DLPF, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011;286:20778–87.CrossRef

23.

Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, et al. Loss of notch2 positively predicts survival in subgroups of human glial brain tumors. PLoS One. 2007;2:e576.CrossRefPubMedPubMedCentral

Title: Decreased expression of microRNA-107 predicts poorer prognosis in glioma
Authors: Yuchen Ji
Yujun Wei
Jianyong Wang
Qiang Ao
Kai Gong
Huancong Zuo
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3086-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target

Association between ADH1B and ADH1C polymorphisms and the risk of head and neck squamous cell carcinoma

Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma

Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma

RETRACTED ARTICLE: Urinary parameters predictive and electrolyte disturbances of cisplatin-induced acute renal associated with cancer as a critical target of the chemotherapeutic agent in patients with solid tumors

Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer